Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus concurrent chemoradiotherapy followed by envafolimab consolidation in unresectable stage III non-small cell lung cancer
ChiCTR2200060332Phase 4Not yet recruiting
- Sponsor
- Jiamusi Cancer Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar, envafolimab, etoposide and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiamusi Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
endostarenvafolimabetoposidecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200060332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060332.